Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 277

1.

68Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis.

Sachpekidis C, Pan L, Hadaschik BA, Kopka K, Haberkorn U, Dimitrakopoulou-Strauss A.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):351-359. eCollection 2018.

2.

Usefulness of positron emission mammography in the evaluation of response to neoadjuvant chemotherapy in patients with breast cancer.

Soldevilla-Gallardo I, Medina-Ornelas SS, Villarreal-Garza C, Bargalló-Rocha E, Caro-Sánchez CH, Hernández-Ramírez R, Estrada-Lobato E.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):341-350. eCollection 2018.

3.

Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

García-Pérez FO, Davanzo J, López-Buenrostro S, Santos-Cuevas C, Ferro-Flores G, Jímenez-Ríos MA, Scavuzzo A, Santana-Ríos Z, Medina-Ornelas S.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):332-340. eCollection 2018.

4.

Somatostatin receptor PET ligands - the next generation for clinical practice.

Pauwels E, Cleeren F, Bormans G, Deroose CM.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):311-331. eCollection 2018. Review.

5.

Chemotherapy-induced coronary arteries calcium score deterioration as detected with unenhanced CT portion of FDG PET/CT.

El-Sabbagh A, Osman MM, Fesler M, Helmy T, Parker N, Muzaffar R.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):303-310. eCollection 2018.

6.

Non-invasive quantification of tumor blood flow in prostate cancer using 15O-H2O PET/CT.

Tolbod LP, Nielsen MM, Pedersen BG, Høyer S, Harms HJ, Borre M, Borghammer P, Bouchelouche K, Frøkiær J, Sørensen J.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):292-302. eCollection 2018.

7.

A dual-labeled cRGD-based PET/optical tracer for pre-operative staging and intraoperative treatment of colorectal cancer.

Sibinga Mulder BG, Handgraaf HJ, Vugts DJ, Sewing C, Windhorst AD, Stammes M, de Geus-Oei LF, Bordo MW, Mieog JSD, van de Velde CJ, Frangioni JV, Vahrmeijer AL.

Am J Nucl Med Mol Imaging. 2018 Oct 20;8(5):282-291. eCollection 2018.

8.

18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer's disease.

Filippi L, Chiaravalloti A, Bagni O, Schillaci O.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):268-281. eCollection 2018. Review.

9.

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Chakravarty R, Siamof CM, Dash A, Cai W.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):247-267. eCollection 2018. Review.

10.

Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia.

Fällmar D, Lilja J, Danfors T, Kilander L, Iyer V, Lubberink M, Larsson EM, Sörensen J.

Am J Nucl Med Mol Imaging. 2018 Aug 20;8(4):239-246. eCollection 2018.

11.

Hepato-splenic axis: hepatic and splenic metabolic activities are linked.

Keramida G, Dunford A, Kaya G, Anagnostopoulos CD, Peters AM.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):228-238. eCollection 2018.

12.

Searching for novel PET radiotracers: imaging cardiac perfusion, metabolism and inflammation.

Davidson CQ, Phenix CP, Tai TC, Khaper N, Lees SJ.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):200-227. eCollection 2018. Review.

13.

Multimodal imaging provides insight into targeted therapy response in metastatic prostate cancer to the bone.

Hoff BA, Brisset JC, Galbán S, Van Dort M, Smith DC, Reichert ZR, Jacobson JA, Luker GD, Chenevert TL, Ross BD.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):189-199. eCollection 2018.

14.

X-ray fluorescence imaging of metals and metalloids in biological systems.

Zhang R, Li L, Sultanbawa Y, Xu ZP.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):169-188. eCollection 2018. Review.

15.

Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison.

Rager O, Lee-Felker SA, Tabouret-Viaud C, Felker ER, Poncet A, Amzalag G, Garibotto V, Zaidi H, Walter MA.

Am J Nucl Med Mol Imaging. 2018 Jun 5;8(3):159-168. eCollection 2018.

16.
17.

CT dose modulation using automatic exposure control in whole-body PET/CT: effects of scout imaging direction and arm positioning.

Inoue Y, Nagahara K, Kudo H, Itoh H.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):143-152. eCollection 2018.

18.

18F-FDG PET/CT findings in hepatosplenic Gamma-Delta T-cell lymphoma: case reports and review of the literature.

Cho MW, Chin BB.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):137-142. eCollection 2018.

19.

Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients.

Nygård L, Aznar MC, Fischer BM, Persson GF, Christensen CB, Andersen FL, Josipovic M, Langer SW, Kjær A, Vogelius IR, Bentzen SM.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):127-136. eCollection 2018.

20.

Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

Salem K, Kumar M, Kloepping KC, Michel CJ, Yan Y, Fowler AM.

Am J Nucl Med Mol Imaging. 2018 Apr 25;8(2):119-126. eCollection 2018.

Supplemental Content

Loading ...
Support Center